Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 4 boards, counting each seat separately. Longest: Collegium Pharmaceutical Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Protalix BioTherapeutics Inc. (DE) June 25, 202693.0%
-
Gain Therapeutics Inc. June 24, 202694.5%
-
Protalix BioTherapeutics Inc. (DE) June 26, 202592.1%
-
Gain Therapeutics Inc. June 24, 202599.5%
-
Protalix BioTherapeutics Inc. (DE) June 27, 202483.7%
-
Gain Therapeutics Inc. June 24, 202470.0%
-
Collegium Pharmaceutical Inc. May 16, 202497.9%
-
Protalix BioTherapeutics Inc. (DE) June 28, 202392.9%
-
Gain Therapeutics Inc. June 23, 202399.5%
-
Collegium Pharmaceutical Inc. May 18, 202398.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 3, 2025 | Protalix BioTherapeutics Inc. (DE) | Grant or award | +7,500 | — | — |
| May 16, 2024 | Collegium Pharmaceutical Inc. | Grant or award | +7,693 | — | — |
| May 18, 2023 | Collegium Pharmaceutical Inc. | Grant or award | +9,792 | — | — |
Questions about Gwen A. Melincoff
What boards is Gwen A. Melincoff on?
Gwen A. Melincoff sits on the boards of Chemomab Therapeutics Ltd. American Depositary Share, Collegium Pharmaceutical Inc., Gain Therapeutics Inc. and Protalix BioTherapeutics Inc. (DE).
How long has Gwen A. Melincoff served on boards?
Our records show at least 10 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.